Stockscreener 앱 받기
1.73
5.98%
-0.11
시장 영업 전:
1.66
-0.07
-4.05%
전일 마감가:
$1.84
열려 있는:
$1.79
하루 거래량:
54,297
Relative Volume:
0.20
시가총액:
$65.33M
수익:
-
순이익/손실:
$-8.82M
주가수익비율:
-5.7667
EPS:
-0.3
순현금흐름:
$-18.01M
1주 성능:
-13.07%
1개월 성능:
-17.62%
6개월 성능:
+71.29%
1년 성능:
+40.09%
1일 변동 폭
$1.67
$1.84
1주일 범위
$1.67
$2.16
52주 변동 폭
$0.7301
$3.15
Estrella Immunopharma Inc Stock (ESLA) Company Profile
명칭
Estrella Immunopharma Inc
전화
(510) 318-9098
주소
5858 HORTON STREET, SUITE 370, EMERYVILLE
ESLA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ESLA
Estrella Immunopharma Inc
|
1.73 | 69.49M | 0 | -8.82M | -18.01M | -0.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Estrella Immunopharma Inc 주식(ESLA)의 최신 뉴스
Estrella Immunopharma secures $3.35M in financing to advance clinical triall; shares up - MSN
Estrella Immunopharma shares gain as CD19 cancer therapy progresses into phase II - MSN
Estrella Immunopharma (ESLA) Stock Analysis Report | Financials & Insights - Benzinga
Estrella’s EB103 advances to Phase II after positive safety data By Investing.com - Investing.com Nigeria
Estrella Immunopharma Advances STARLIGHT-1 Trial to Phase II - TradingView — Track All Markets
Estrella Immunopharma stock rises as cancer therapy advances to Phase II - Investing.com Canada
Estrella’s EB103 advances to Phase II after positive safety data - Investing.com
Estrella advances Starlight-1 trial into phase II following positive DSMB recommendation - marketscreener.com
Estrella (NASDAQ: ESLA) passes DSMB; EB103 high-dose cohort reports 100% CR - Stock Titan
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation - Business Wire
Is Estrella Immunopharma Inc. stock a defensive play in 2025Portfolio Gains Summary & Daily Growth Stock Investment Tips - Newser
Here's Why We're Not Too Worried About Estrella Immunopharma's (NASDAQ:ESLA) Cash Burn Situation - Sahm
Estrella Immunopharma (NASDAQ:ESLA) Raised to “Hold” at Wall Street Zen - Defense World
Estrella Immunopharma (NASDAQ:ESLA) Raised to "Hold" at Wall Street Zen - MarketBeat
How Estrella Immunopharma Inc. stock benefits from global expansionInsider Buying & Free Technical Pattern Based Buy Signals - newser.com
Published on: 2025-11-19 23:49:15 - newser.com
Is Estrella Immunopharma Inc. stock oversold or undervaluedStock Surge & Free High Accuracy Swing Entry Alerts - newser.com
What data driven models say about Estrella Immunopharma Inc.’s futureJuly 2025 Highlights & Capital Protection Trade Alerts - newser.com
Is now a turning point for Estrella Immunopharma Inc.July 2025 Chart Watch & Advanced Technical Analysis Signals - newser.com
Is Estrella Immunopharma Inc. building a consolidation baseMarket Trend Review & Precise Buy Zone Tips - newser.com
Will Estrella Immunopharma Inc. stock gain from government policies2025 Key Lessons & AI Driven Stock Price Forecasts - newser.com
Published on: 2025-11-15 19:23:21 - newser.com
Is Estrella Immunopharma Inc. reversing from oversold territoryEntry Point & Step-by-Step Swing Trade Plans - newser.com
How to integrate Estrella Immunopharma Inc. into portfolio analysis tools - newser.com
Published on: 2025-11-14 10:46:07 - newser.com
10-Q: Quarterly report - 富途牛牛
Estrella Immunopharma Inc (ESLA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):